In vitro inhibitory activities of magnolol againstCandida spp
Candida spp. cause various infections involving the skin, mucosa, deep tissues, and even life-threatening candidemia. They are regarded as an important pathogen of nosocomial bloodstream infection, with a high mortality rate. As a result of prolonged exposure to azoles, the therapeutic failure assoc...
Gespeichert in:
| Veröffentlicht in: | Drug design, development and therapy development and therapy, 2017-01, Vol.11, p.2653 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 2653 |
| container_title | Drug design, development and therapy |
| container_volume | 11 |
| creator | Zhou, Peiru Fu, Jingya Hong, Hua Liu, Xiaosong |
| description | Candida spp. cause various infections involving the skin, mucosa, deep tissues, and even life-threatening candidemia. They are regarded as an important pathogen of nosocomial bloodstream infection, with a high mortality rate. As a result of prolonged exposure to azoles, the therapeutic failure associated with azoles resistance has become a serious challenge in clinical situations. Therefore, novel, alternative antifungals are required urgently. In the present study, the CLSI M-27A broth microdilution method and the 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay were used to evaluate the antifungal effects of magnolol against various standard Candida strains in planktonic mode and biofilm formation, respectively. The antifungal activity of magnolol was demonstrated in planktonic C. albicans and non-albicans Candida species, especially fluconazole-resistant Candida krusei, with the minimum inhibitory concentrations ranging from 10 to 40 µg/mL. The BMIC90 (minimum concentration with 90% Candida biofilm inhibited) values of magnolol ranged from 20 to 160 µg/mL, whereas the BMIC90 values of fluconazole were more than 128 µg/mL. As an alternative and broad-spectrum antifungal agent, magnolol might be of benefit to the treatment of refractory Candida infection. |
| doi_str_mv | 10.2147/DDDT.S146529 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2226362056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2226362056</sourcerecordid><originalsourceid>FETCH-proquest_journals_22263620563</originalsourceid><addsrcrecordid>eNqNjbsKwjAYRoMgWC-bDxBwbk3SNq2DU6vobPcS7cW_1CQmqeDbW8QHcPrgnAMfQmtKAkajZJvneRFcaMRjtpsgj9Ik8dM0pTM0t7YjhIecEQ_tzxK_wBmFQd7hCk6ZNxY3ByOE2mLV4IdopepVj0UrQFqXCVlBJbDVeommjehtvfrtAm2OhyI7-dqo51BbV3ZqMHJUJWPsexnz8L_qA6U1PD8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2226362056</pqid></control><display><type>article</type><title>In vitro inhibitory activities of magnolol againstCandida spp</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Zhou, Peiru ; Fu, Jingya ; Hong, Hua ; Liu, Xiaosong</creator><creatorcontrib>Zhou, Peiru ; Fu, Jingya ; Hong, Hua ; Liu, Xiaosong</creatorcontrib><description>Candida spp. cause various infections involving the skin, mucosa, deep tissues, and even life-threatening candidemia. They are regarded as an important pathogen of nosocomial bloodstream infection, with a high mortality rate. As a result of prolonged exposure to azoles, the therapeutic failure associated with azoles resistance has become a serious challenge in clinical situations. Therefore, novel, alternative antifungals are required urgently. In the present study, the CLSI M-27A broth microdilution method and the 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay were used to evaluate the antifungal effects of magnolol against various standard Candida strains in planktonic mode and biofilm formation, respectively. The antifungal activity of magnolol was demonstrated in planktonic C. albicans and non-albicans Candida species, especially fluconazole-resistant Candida krusei, with the minimum inhibitory concentrations ranging from 10 to 40 µg/mL. The BMIC90 (minimum concentration with 90% Candida biofilm inhibited) values of magnolol ranged from 20 to 160 µg/mL, whereas the BMIC90 values of fluconazole were more than 128 µg/mL. As an alternative and broad-spectrum antifungal agent, magnolol might be of benefit to the treatment of refractory Candida infection.</description><identifier>EISSN: 1177-8881</identifier><identifier>DOI: 10.2147/DDDT.S146529</identifier><language>eng</language><publisher>Macclesfield: Taylor & Francis Ltd</publisher><subject>Antifungal activity ; Antifungal agents ; Azoles ; Biofilms ; Candida ; Candidemia ; Epidemiology ; Fluconazole ; Fungicides ; Health surveillance ; Heterocyclic compounds ; HIV ; Hospitals ; Human immunodeficiency virus ; Infections ; Mucosa ; Nosocomial infection ; Nosocomial infections ; Pathogens ; Skin ; Sterols ; Trends ; Yeast</subject><ispartof>Drug design, development and therapy, 2017-01, Vol.11, p.2653</ispartof><rights>2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids></links><search><creatorcontrib>Zhou, Peiru</creatorcontrib><creatorcontrib>Fu, Jingya</creatorcontrib><creatorcontrib>Hong, Hua</creatorcontrib><creatorcontrib>Liu, Xiaosong</creatorcontrib><title>In vitro inhibitory activities of magnolol againstCandida spp</title><title>Drug design, development and therapy</title><description>Candida spp. cause various infections involving the skin, mucosa, deep tissues, and even life-threatening candidemia. They are regarded as an important pathogen of nosocomial bloodstream infection, with a high mortality rate. As a result of prolonged exposure to azoles, the therapeutic failure associated with azoles resistance has become a serious challenge in clinical situations. Therefore, novel, alternative antifungals are required urgently. In the present study, the CLSI M-27A broth microdilution method and the 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay were used to evaluate the antifungal effects of magnolol against various standard Candida strains in planktonic mode and biofilm formation, respectively. The antifungal activity of magnolol was demonstrated in planktonic C. albicans and non-albicans Candida species, especially fluconazole-resistant Candida krusei, with the minimum inhibitory concentrations ranging from 10 to 40 µg/mL. The BMIC90 (minimum concentration with 90% Candida biofilm inhibited) values of magnolol ranged from 20 to 160 µg/mL, whereas the BMIC90 values of fluconazole were more than 128 µg/mL. As an alternative and broad-spectrum antifungal agent, magnolol might be of benefit to the treatment of refractory Candida infection.</description><subject>Antifungal activity</subject><subject>Antifungal agents</subject><subject>Azoles</subject><subject>Biofilms</subject><subject>Candida</subject><subject>Candidemia</subject><subject>Epidemiology</subject><subject>Fluconazole</subject><subject>Fungicides</subject><subject>Health surveillance</subject><subject>Heterocyclic compounds</subject><subject>HIV</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Infections</subject><subject>Mucosa</subject><subject>Nosocomial infection</subject><subject>Nosocomial infections</subject><subject>Pathogens</subject><subject>Skin</subject><subject>Sterols</subject><subject>Trends</subject><subject>Yeast</subject><issn>1177-8881</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjbsKwjAYRoMgWC-bDxBwbk3SNq2DU6vobPcS7cW_1CQmqeDbW8QHcPrgnAMfQmtKAkajZJvneRFcaMRjtpsgj9Ik8dM0pTM0t7YjhIecEQ_tzxK_wBmFQd7hCk6ZNxY3ByOE2mLV4IdopepVj0UrQFqXCVlBJbDVeommjehtvfrtAm2OhyI7-dqo51BbV3ZqMHJUJWPsexnz8L_qA6U1PD8</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Zhou, Peiru</creator><creator>Fu, Jingya</creator><creator>Hong, Hua</creator><creator>Liu, Xiaosong</creator><general>Taylor & Francis Ltd</general><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20170101</creationdate><title>In vitro inhibitory activities of magnolol againstCandida spp</title><author>Zhou, Peiru ; Fu, Jingya ; Hong, Hua ; Liu, Xiaosong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_22263620563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antifungal activity</topic><topic>Antifungal agents</topic><topic>Azoles</topic><topic>Biofilms</topic><topic>Candida</topic><topic>Candidemia</topic><topic>Epidemiology</topic><topic>Fluconazole</topic><topic>Fungicides</topic><topic>Health surveillance</topic><topic>Heterocyclic compounds</topic><topic>HIV</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Infections</topic><topic>Mucosa</topic><topic>Nosocomial infection</topic><topic>Nosocomial infections</topic><topic>Pathogens</topic><topic>Skin</topic><topic>Sterols</topic><topic>Trends</topic><topic>Yeast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Peiru</creatorcontrib><creatorcontrib>Fu, Jingya</creatorcontrib><creatorcontrib>Hong, Hua</creatorcontrib><creatorcontrib>Liu, Xiaosong</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Drug design, development and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Peiru</au><au>Fu, Jingya</au><au>Hong, Hua</au><au>Liu, Xiaosong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro inhibitory activities of magnolol againstCandida spp</atitle><jtitle>Drug design, development and therapy</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>11</volume><spage>2653</spage><pages>2653-</pages><eissn>1177-8881</eissn><abstract>Candida spp. cause various infections involving the skin, mucosa, deep tissues, and even life-threatening candidemia. They are regarded as an important pathogen of nosocomial bloodstream infection, with a high mortality rate. As a result of prolonged exposure to azoles, the therapeutic failure associated with azoles resistance has become a serious challenge in clinical situations. Therefore, novel, alternative antifungals are required urgently. In the present study, the CLSI M-27A broth microdilution method and the 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay were used to evaluate the antifungal effects of magnolol against various standard Candida strains in planktonic mode and biofilm formation, respectively. The antifungal activity of magnolol was demonstrated in planktonic C. albicans and non-albicans Candida species, especially fluconazole-resistant Candida krusei, with the minimum inhibitory concentrations ranging from 10 to 40 µg/mL. The BMIC90 (minimum concentration with 90% Candida biofilm inhibited) values of magnolol ranged from 20 to 160 µg/mL, whereas the BMIC90 values of fluconazole were more than 128 µg/mL. As an alternative and broad-spectrum antifungal agent, magnolol might be of benefit to the treatment of refractory Candida infection.</abstract><cop>Macclesfield</cop><pub>Taylor & Francis Ltd</pub><doi>10.2147/DDDT.S146529</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1177-8881 |
| ispartof | Drug design, development and therapy, 2017-01, Vol.11, p.2653 |
| issn | 1177-8881 |
| language | eng |
| recordid | cdi_proquest_journals_2226362056 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Antifungal activity Antifungal agents Azoles Biofilms Candida Candidemia Epidemiology Fluconazole Fungicides Health surveillance Heterocyclic compounds HIV Hospitals Human immunodeficiency virus Infections Mucosa Nosocomial infection Nosocomial infections Pathogens Skin Sterols Trends Yeast |
| title | In vitro inhibitory activities of magnolol againstCandida spp |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T07%3A12%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20inhibitory%20activities%20of%20magnolol%20againstCandida%20spp&rft.jtitle=Drug%20design,%20development%20and%20therapy&rft.au=Zhou,%20Peiru&rft.date=2017-01-01&rft.volume=11&rft.spage=2653&rft.pages=2653-&rft.eissn=1177-8881&rft_id=info:doi/10.2147/DDDT.S146529&rft_dat=%3Cproquest%3E2226362056%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2226362056&rft_id=info:pmid/&rfr_iscdi=true |